Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (Q57579888)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 March 2014

Language	Label	Description	Also known as
English	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort	scientific article published on 20 March 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Vladimir Semiglazov

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Wolfgang Eiermann

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Sergei Tjulandin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Milvia Zambetti

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Angela Moliterni

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Federico Vazquez

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Mikhail J Byakhov

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Mikhail Lichinitser

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Miguel Angel Climent

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Belen Ojeda

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Mauro Mansutti

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Alla Bozhok

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Domenico Magazzù

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Dominik Heinzmann

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Jutta Steinseifer

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Pinuccia Valagussa

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Jose Baselga

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

20 March 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

640-647

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and accelerated drug approval in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70080-4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57579888&oldid=2032404207"